Fluvastatin Na
HMG CoA reductase inhibitor / Potent inhibitor of HMG-CoA reductase, IC50=40-100 nM.1 Clinically useful, orally active antihypercholesterolemic agent. Inhibits vascular smooth muscle proliferation, IC50=70 nM.2 Displays antineuroinflammatory activity.3 Prevents lung adenocarcinoma bone metastasis by triggering autophagy.4 Attenuates cell proliferation in hepatocellular carcinoma.5
Biochemicals & reagents
93957-55-2
1) Dansette et al. (2000), HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins; Exp. Toxicol. Pathol., 52 145 2) Turner et al. (2007), Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion: J. Cardiovasc. Pharmacol., 50 458 3) McFarland et al. (2017), Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-like Cells; Mediators Inflamm., Epub May 4 4) Yang et al. (2017), Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy; EBioMedicine, 19 49 5) Higashi et al. (2016), Statin attenuates cell proplerative ability via TAZ (WWTR1) in hepatocellular carcinoma; Med. Oncol., 33 123
-20°C
TARGET: HMG-CoA reductase -- PATHWAY: Autophagy; Cholesterol metabolism; Proliferation -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer; AtherosclerosisHeart disease